Abstract: The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.

Abstract: This invention relates to mutant forms of carboxypeptidase U with increased thermal stability relative to wild-type. In addition to the individual thermal stabilizing mutations identified (at positions 166, 204, 219, 230, 251, 315), the inventors have identified a region (S327-H357) that is crucial to the stability of CPU. The invention relates to nucleic acid encoding such mutant forms and the polypeptides encoded thereby. The invention also relates to methods and materials for making CPU mutants with increased thermal stability relative to wild-type and their use, for example to produce crystals of CPU or proCPU for 3-dimensional structure determination, or in therapy.

Abstract: The administration of cannabinoid receptor agonists for inhibition of transient lower esophageal sphincter relaxations, gastroesophageal reflux disease and regurgitation is disclosed.